PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0045-1809350
Original Article

A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer

Pongwut Danchaivijitr
1   Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
,
Anita Archwamety 
1   Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
,
Concord Wongkraisri
1   Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
› Author Affiliations
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Background

Prostate cancer ranks as the eighth leading cause of cancer-related mortality in Thailand, exhibiting an average annual percent increase in incidence rates of 2.7%. Abiraterone acetate, an active prodrug of abiraterone, exhibits potent inhibitory activity against the enzyme CYP17A1, a crucial component in the androgenic biosynthetic cascade. This study was designed to evaluate the safety and efficacy of generic abiraterone (Abiratred) in treating metastatic prostate cancer within a real-world, retrospective observational context.

Materials and Methods

Thirty-five patients diagnosed with metastatic prostate cancer who underwent abiraterone treatment at Siriraj Hospital in Thailand were enrolled in the study. Data encompassing demographics, medical history, general examination, vital signs, comorbidities, health status, and prostate cancer-related characteristics were collected. The primary outcome measure was the prostate-specific antigen (PSA) response rate (defined as a ≥ 50% decrease in PSA levels from baseline), and secondary outcomes encompassed assessing PSA progression-free survival (PFS), disease control rate (DCR), and evaluating safety.

Results

Among the 35 patients, 23 (65.7%) exhibited a PSA response. The median PSA PFS at 6 months was 65.6% (21 out of 35 patients). The DCR was determined to be 71.4% (25 out of 35 patients), with 19 (54.3%) patients experiencing stable disease and 6 (17.1%) patients showing a partial response. Adverse events were observed in 5 (14.3%) patients, but there were no deaths related to abiraterone.

Conclusion

This real-world study provides evidence that generic abiraterone (Abiratred) is both well-tolerated and effective for patients with advanced or metastatic prostate cancer, making it a promising option in real-world clinical settings.

Keywords

abiraterone - androgen deprivation therapy - prostate cancer - prostate-specific antigen - real-world study

Authors' Contributions

A.A. and C.W. performed patient data collection and data review. P.D. reviewed and finalized the data analysis and manuscript. All authors have reviewed the final manuscript.


Data Availability Statement

The patient data used to support this study's findings are available from the corresponding author upon request.




Publication History

Received: 13 July 2024

Accepted: 02 May 2025

Article published online:
20 June 2025

© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India